OPENCLINICAL C.I.C.

Company limited by guarantee

Company Registration Number:
09809042 (England and Wales)

Unaudited statutory accounts for the year ended 31 October 2024

Period of accounts

Start date: 1 November 2023

End date: 31 October 2024

OPENCLINICAL C.I.C.

Contents of the Financial Statements

for the Period Ended 31 October 2024

Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

OPENCLINICAL C.I.C.

Profit And Loss Account

for the Period Ended 31 October 2024

2024 2023


£

£
Turnover: 6,087 2,745
Gross profit(or loss): 6,087 2,745
Administrative expenses: ( 1,099 ) ( 2,139 )
Operating profit(or loss): 4,988 606
Profit(or loss) before tax: 4,988 606
Profit(or loss) for the financial year: 4,988 606

OPENCLINICAL C.I.C.

Balance sheet

As at 31 October 2024

Notes 2024 2023


£

£
Current assets
Cash at bank and in hand: 5,630 1,995
Total current assets: 5,630 1,995
Creditors: amounts falling due within one year: 3 ( 642 ) ( 92,321 )
Net current assets (liabilities): 4,988 (90,326)
Total assets less current liabilities: 4,988 ( 90,326)
Total net assets (liabilities): 4,988 (90,326)
Members' funds
Profit and loss account: 4,988 ( 90,326)
Total members' funds: 4,988 (90,326)

The notes form part of these financial statements

OPENCLINICAL C.I.C.

Balance sheet statements

For the year ending 31 October 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 31 May 2025
and signed on behalf of the board by:

Name: Dr Matthew South
Status: Director

The notes form part of these financial statements

OPENCLINICAL C.I.C.

Notes to the Financial Statements

for the Period Ended 31 October 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

OPENCLINICAL C.I.C.

Notes to the Financial Statements

for the Period Ended 31 October 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 0

OPENCLINICAL C.I.C.

Notes to the Financial Statements

for the Period Ended 31 October 2024

3. Creditors: amounts falling due within one year note

2024 2023
£ £
Other creditors 642 92,321
Total 642 92,321

OPENCLINICAL C.I.C.

Notes to the Financial Statements

for the Period Ended 31 October 2024

4. Loans to directors

Name of director receiving advance or credit:
Description of the transaction:
Unpaid Sales Invoices
£
Balance at 31 October 2023 92,321
Advances or credits made:
Advances or credits repaid:
Balance at 31 October 2024 92,321

COMMUNITY INTEREST ANNUAL REPORT

OPENCLINICAL C.I.C.

Company Number: 09809042 (England and Wales)

Year Ending: 31 October 2024

Company activities and impact

During this year the Company agreed it first commercial license with a Uk company and it continues to support its open source PROforma implementation , as can be seen at Https://gitlab.com/openclinical. It also participated in three UK funded research projects and looks forward to the trialling of a destination decision support system for the Ambulance service in Rwanda and the further development of CDSS to support care for patients with multimorbidity in Sri Lanka.

Consultation with stakeholders

The company's stakeholders are global health technology and publishing and other entities including government agencies and care providers and professionals. Stakeholders are engaged and consulted via publications and demonstrations and the provision of the OpenClinical open access and open source repositories.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
31 May 2025

And signed on behalf of the board by:
Name: Dr Matthew South
Status: Director